Better Therapeutics Inc. (NASDAQ:BTTX) saw an upside of 0.35% to $0.71 after subtracting $0.0 on Monday. The 5-day average trading volume is 524,697 shares of the company’s common stock. It has gained $0.8100 in the past week and touched a new high 1 time within the past 5 days. An average of 2,265,719 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,100,630.
BTTX’s 1-month performance is -36.61% or -$0.4012 on its low of $0.5700 reached on 07/27/23. The company’s shares have touched a 52-week low of $0.57 and high of $2.17, with the stock’s rally to the 52-week high happening on 04/10/23. YTD, BTTX has lost -35.75% or -$0.3862 and has reached a new high 10 times. However, the current price is down -67.28% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
BTTX stock has a beta of 1.84.
Better Therapeutics Inc.’s quick ratio for the period ended March 30 was 0.60, with the current ratio over the same period at 0.60.
Earnings Surprise
For the quarterly period ending March 30 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -3.21% to -$9.36 million, while revenue of -$8.77 million was 6.3% off the previous quarter. Analysts expected BTTX to announce -$0.74 per share in earnings in its latest quarter, but it posted -$0.39, representing a 47.30% surprise. EBITDA for the quarter stood at more than -$8.17 million. BTTX stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 22.64 million, with total debt at $14.54 million. Shareholders hold equity totaling $31.73 million.
Let’s look briefly at Better Therapeutics Inc. (BTTX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 04 August was 43.63% to suggest the stock is trending Neutral, with historical volatility in this time period at 105.90%.
The stock’s 5-day moving average is $0.7183, reflecting a -3.71% or -$0.0277 change from its current price. BTTX is currently trading -20.13% above its 20-day SMA, -25.16% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -2.86% and SMA200 by-53.92%.
Stochastic %K and %D was 49.62% and 47.97% and the average true range (ATR) pointed at 0.0874. The RSI (14) points at 42.99%, while the 14-day stochastic is at 52.21% with the period’s ATR at 0.0971. The stock’s 9-day MACD Oscillator is pointing at 0.0253 and 0.0073 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Better Therapeutics Inc. (NASDAQ: BTTX), Chardan Capital Markets launched coverage with a Buy rating. Analysts offering their rating for BTTX stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate BTTX as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 3 have offered a “buy” rating.
What is BTTX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $5.00 and a high of $9.00, with their median price target at $7.00. Looking at these predictions, the average price target given by analysts is for Better Therapeutics Inc. (BTTX) stock is $7.00.
